Safety and efficacy of cryopreserved autologous platelet concentrates in HLA-alloimmunized patients with hematologic malignancies

Transfusion

Volumn 56, Issue 10, 2016, Pages 2426-2437

  Gerber, Bernhard ^a,e   Alberio, Lorenzo ^b,c   Rochat, Sophie ^b   Stenner, Frank ^d   Manz, Markus G ^a   Buser, Andy ^d   Schanz, Urs ^a   Stussi, Georg ^e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CONVULXIN; HLA ANTIGEN; THROMBIN; THROMBOCYTE CONCENTRATE; DIMETHYL SULFOXIDE;

ACUTE LEUKEMIA; ADULT; AGED; ALLOIMMUNIZATION; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HEMATOLOGIC MALIGNANCY; HUMAN; MIDDLE AGED; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPHERESIS; AUTOTRANSPLANTATION; BLEEDING; CYTOLOGY; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; PATIENT SAFETY; PHYSIOLOGY; PROCEDURES; STANDARDS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BLOOD PLATELETS; CRYOPRESERVATION; DIMETHYL SULFOXIDE; FEMALE; FLOW CYTOMETRY; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; HLA ANTIGENS; HUMANS; MIDDLE AGED; PATIENT SAFETY; PLATELET ACTIVATION; PLATELET TRANSFUSION; PLATELETPHERESIS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84976871172     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13690     Document Type: Article

References (25)

1. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962;266:905–9.
2. Djerassi I, Farber S, Evans AE. Transfusions of fresh platelet concentrates to patients with secondary thrombocytopenia. N Engl J Med 1963;268:221–6.
3. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012;380:1309–16.
4. Gmür J, Burger J, Schanz U, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991;338:1223–6.
5. [No authors listed]. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997;337:1861–9.
6. Valeri CR. Hemostatic effectiveness of liquid-preserved and previously frozen human platelets. N Engl J Med 1974;290:353–8.
7. Schiffer CA, Aisner J, Wiernik PH. Clinical experience with transfusion of cryopreserved platelets. Br J Haematol 1976;34:377–85.
8. Schiffer CA, Aisner J, Wiernik PH. Frozen autologous platelet transfusion for patients with leukemia. N Engl J Med 1978;299:7–12.
9. Daly PA, Schiffer CA, Aisner J, et al. Successful transfusion of platelets cryopreserved for more than 3 years. Blood 1979;54:1023–7.
10. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207–14.
11. Josephson CD, Granger S, Assmann SF, et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 2012;120:748–60.
12. Pei R, Lee J, Chen T, et al. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 1999;60:1293–302.
13. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003;75:43–9.
14. Daskalakis M, Colucci G, Keller P, et al. Decreased generation of procoagulant platelets detected by flow cytometric analysis in patients with bleeding diathesis. Cytometry B Clin Cytom 2014;86:397–409.
15. Alberio L, Safa O, Clemetson KJ, et al. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000;95:1694–702.
16. Wall JE, Buijs-Wilts M, Arnold JT, et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 1995;89:380–5.
17. Sniecinski I, O'Donnell MR, Nowicki B, et al. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988;71:1402–7.
18. Murphy MF, Metcalfe P, Thomas H, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986;62:529–34.
19. Karafin M, Fuller AK, Savage WJ, et al. The impact of apheresis platelet manipulation on corrected count increment. Transfusion 2012;52:1221–7.
20. Valeri CR, Ragno G, Khuri S. Freezing human platelets with 6 percent dimethyl sulfoxide with removal of the supernatant solution before freezing and storage at −80 degrees C without postthaw processing. Transfusion 2005;45:1890–8.
21. Pedrazzoli P, Noris P, Perotti C, et al. Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia: a pilot study. Br J Haematol 2000;108:653–9.
22. Schiffer CA, Buchholz DH, Aisner J, et al. Frozen autologous platelets in the supportive care of patients with leukemia. Transfusion 1976;16:321–9.
23. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106–14.
24. Cid J, Escolar G, Galan A, et al. In vitro evaluation of the hemostatic effectiveness of cryopreserved platelets. Transfusion 2016;56:580–6.
25. Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet 2002;359:2145–52.